Arbutus Biopharma Corp Stock Current Valuation
| ABUS Stock | USD 3.20 0.02 0.62% |
Valuation analysis of Arbutus Biopharma Corp helps investors to measure Arbutus Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 375.5 M in 2025, despite the fact that Enterprise Value Over EBITDA is likely to grow to (6.12). Fundamental drivers impacting Arbutus Biopharma's valuation include:
Undervalued
Today
Please note that Arbutus Biopharma's price fluctuation is slightly risky at this time. Calculation of the real value of Arbutus Biopharma Corp is based on 3 months time horizon. Increasing Arbutus Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Arbutus stock is determined by what a typical buyer is willing to pay for full or partial control of Arbutus Biopharma Corp. Since Arbutus Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arbutus Stock. However, Arbutus Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.2 | Real 4.13 | Target 5.08 | Hype 3.2 | Naive 3.31 |
The intrinsic value of Arbutus Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Arbutus Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Arbutus Biopharma Corp helps investors to forecast how Arbutus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arbutus Biopharma more accurately as focusing exclusively on Arbutus Biopharma's fundamentals will not take into account other important factors: Arbutus Biopharma Corp Company Current Valuation Analysis
Arbutus Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Arbutus Biopharma Current Valuation | 480.03 M |
Most of Arbutus Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arbutus Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arbutus Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Arbutus Biopharma is extremely important. It helps to project a fair market value of Arbutus Stock properly, considering its historical fundamentals such as Current Valuation. Since Arbutus Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arbutus Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arbutus Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Arbutus Current Valuation Historical Pattern
Today, most investors in Arbutus Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arbutus Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Arbutus Biopharma current valuation as a starting point in their analysis.
Arbutus Biopharma Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Arbutus Biopharma Corp has a Current Valuation of 480.03 M. This is 96.66% lower than that of the Biotechnology sector and 89.67% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.11% higher than that of the company.
Arbutus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arbutus Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arbutus Biopharma could also be used in its relative valuation, which is a method of valuing Arbutus Biopharma by comparing valuation metrics of similar companies.Arbutus Biopharma is currently under evaluation in current valuation category among its peers.
Arbutus Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arbutus Biopharma from analyzing Arbutus Biopharma's financial statements. These drivers represent accounts that assess Arbutus Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arbutus Biopharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 269.2M | 413.3M | 351.7M | 414.9M | 373.4M | 392.1M | |
| Enterprise Value | 219.9M | 306.6M | 323.1M | 397.3M | 357.6M | 375.5M |
Arbutus Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arbutus Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arbutus Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Arbutus Fundamentals
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (13.05) % | ||||
| Current Valuation | 480.03 M | ||||
| Shares Outstanding | 189.49 M | ||||
| Shares Owned By Insiders | 22.22 % | ||||
| Shares Owned By Institutions | 53.85 % | ||||
| Number Of Shares Shorted | 5.95 M | ||||
| Price To Earning | (1.16) X | ||||
| Price To Book | 5.67 X | ||||
| Price To Sales | 89.94 X | ||||
| Revenue | 18.14 M | ||||
| Gross Profit | (56.05 M) | ||||
| EBITDA | (70.99 M) | ||||
| Net Income | (72.85 M) | ||||
| Cash And Equivalents | 150.2 M | ||||
| Cash Per Share | 1.00 X | ||||
| Total Debt | 8.72 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (85.94 M) | ||||
| Short Ratio | 6.88 X | ||||
| Earnings Per Share | (0.43) X | ||||
| Target Price | 5.11 | ||||
| Number Of Employees | 73 | ||||
| Beta | 1.92 | ||||
| Market Capitalization | 606.37 M | ||||
| Total Asset | 144.4 M | ||||
| Retained Earnings | (1.28 B) | ||||
| Working Capital | 109.54 M | ||||
| Current Asset | 183.88 M | ||||
| Current Liabilities | 10.58 M | ||||
| Net Asset | 144.4 M |
About Arbutus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arbutus Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.